Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.
Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.
复制标题
DOI：
10.1158/1078-0432.ccr-09-0520
复制
发表时间：
2009-08-15
期刊：
影响因子：
--
通讯作者：
Sandler A
中科院分区：
文献类型：
--
作者：
Horn L;Sandler A
非小细胞肺癌（NSCLC）是一个主要的全球健康问题，是世界范围内癌症相关死亡的主要原因。大多数NSCLC患者被诊断为晚期疾病，这类患者的预后较差。目前批准的细胞毒性化疗在有效性和安全性方面都有很大的局限性。靶向表皮生长因子受体（EGFR）的药物以及抗血管生成药物贝伐单抗的可用性已经提供了一些临床益处。然而，这些药物的疗效也不足，耐药性已成为一个临床问题。许多新的靶向治疗目前正在临床开发中，可能有潜力克服与现有药物相关的局限性。在本文中，我们回顾了非小细胞肺癌分子靶向治疗的临床数据，重点是EGFR抑制剂和抗血管生成药物。
Non-small cell lung cancer (NSCLC) is a major global health problem and represents the leading cause of cancer-related deaths worldwide. The majority of patients with NSCLC are diagnosed with advanced-stage disease, and the prognosis for such patients is poor. The currently approved cytotoxic chemotherapy is associated with substantial limitations in both efficacy and safety. The availability of agents targeted against the epidermal growth factor receptor (EGFR), as well as the antiangiogenic agent bevacizumab, have provided some clinical benefit. Nonetheless, the efficacy of these agents is also inadequate, and resistance has emerged as a clinical problem. Numerous novel targeted therapies are now in clinical development and may have potential for overcoming the limitations associated with currently available agents. In this article we review clinical data for molecular-targeted therapies in NSCLC, with emphasis on EGFR inhibitors and antiangiogenic agents.